Status:
UNKNOWN
The Effects of Microbiota Composition on Immunosuppression Protocols in Transplantation
Lead Sponsor:
Université Catholique de Louvain
Conditions:
Kidney Transplant; Complications
Immunosuppression
Eligibility:
All Genders
18-75 years
Brief Summary
Solid organ transplantation is the treatment of choice for patients suffering from end-stage organ disease, including for chronic kidney failure. The implementation of effective immunosuppressive ther...
Detailed Description
Solid-organ transplantation often requires the implementation of a lifelong immunosuppressive therapy. A combination of tacrolimus (TAC), mycophenolate mofetil (MMF), together with steroids is current...
Eligibility Criteria
Inclusion
- Patients within 1 to 8 years post transplantation
- Aged between 18 and 75 years old
- Patients receiving tacrolimus and mycophenolate mofetil as part of their immunosuppressive therapy
- French speaking
- BMI between 18 and 30.
Exclusion
- Use of tobacco
- Potential Alcohol problems (less than two positive answers to the CAGE questionnaire)
- Use of antibiotic medication within 3 months of the sample collection
- Use of laxative medication within 2 weeks of the sample collection
- Use of anti-fungal medication within 2 weeks of the sample collection
- Pregnant or lactating patients.
Key Trial Info
Start Date :
February 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04360031
Start Date
February 10 2020
End Date
March 1 2021
Last Update
April 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques universitaires Saint-Luc
Brussels, Belgium, 1200